PE20060366A1 - AMINOPYRIDINE DERIVATIVES AS DOPAMINE AGONISTS - Google Patents

AMINOPYRIDINE DERIVATIVES AS DOPAMINE AGONISTS

Info

Publication number
PE20060366A1
PE20060366A1 PE2005000583A PE2005000583A PE20060366A1 PE 20060366 A1 PE20060366 A1 PE 20060366A1 PE 2005000583 A PE2005000583 A PE 2005000583A PE 2005000583 A PE2005000583 A PE 2005000583A PE 20060366 A1 PE20060366 A1 PE 20060366A1
Authority
PE
Peru
Prior art keywords
alkyl
pyridin
amine
optionally substituted
dopamine agonists
Prior art date
Application number
PE2005000583A
Other languages
Spanish (es)
Inventor
Andrew Simon Cook
David Hepworth
Charlotte Moira Norfor Allerton
Duncan Charles Miller
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060366(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0411891A external-priority patent/GB0411891D0/en
Priority claimed from GB0412463A external-priority patent/GB0412463D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20060366A1 publication Critical patent/PE20060366A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE AMINOPIRIDINA DE FORMULA (I), EN DONDE R1 Y R2 SON INDEPENDIENTEMENTE H Y ALQUILO(C1-C6); R3 ES (II), (III) Y (IV), EN DONDE A ES O, S O CH2; n ES 1 O 2; R4 ES H O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON 1 O 2 ALQUILO(C1-C6), OR7, FENILO Y HETEROARILO; R5 ESH O ALQUILO(C1-C6), OPCIONALMENTE SUSTITUIDO CON OR7; R6 ES H O ALQUILO(C1-C6); R7 ES R6 DONDE AL ALQUILO PUEDE SER SUSTITUIDO POR FENILO OPCIONALMENTE SUSTITUIDO. SON PREFERIDOS: 5-(MORFOLIN-2-IL)PIRIDIN-2-AMINA, 5-[(2S,5S)-5-METIL-4-(3-FENILPROPIL)MORFOLIN-2-IL}PIRIDIN-2-AMINA, 5-[(2S,5S)-4,5-DIETILMORFOLIN-2-IL}PIRIDIN-2-AMINA; ENTRE OTROS. ESTOS COMPUESTOS SON AGONISTAS SELECTIVOS DE LA DOPAMINA D3, Y SON UTILES EN EL TRATAMIENTO Y/O PREVENCION DE DISFUNCION SEXUAL FEMENINA O MASCULINA Y ENFERMEDADES RELACIONADASREFERS TO AMINOPYRIDINE DERIVATIVE COMPOUNDS OF FORMULA (I), WHERE R1 AND R2 ARE INDEPENDENTLY H AND ALKYL (C1-C6); R3 IS (II), (III) AND (IV), WHERE A IS O, S O CH2; n IS 1 O 2; R4 IS H OR ALKYL (C1-C6) OPTIONALLY SUBSTITUTED WITH 1 OR 2 ALKYL (C1-C6), OR7, PHENYL AND HETEROARYL; R5 ESH OR ALKYL (C1-C6), OPTIONALLY SUBSTITUTED WITH OR7; R6 IS HO (C1-C6) ALKYL; R7 IS R6 WHERE THE RENT CAN BE SUBSTITUTED BY OPTIONALLY SUBSTITUTED PHENYL. THE PREFERRED ARE: 5- (MORPHOLIN-2-IL) PYRIDIN-2-AMINE, 5 - [(2S, 5S) -5-METHYL-4- (3-PHENYLPROPYL) MORFOLIN-2-IL} PYRIDIN-2-AMINE, 5 - [(2S, 5S) -4,5-DIETHYLMORPHOLIN-2-IL} PYRIDIN-2-AMINE; AMONG OTHERS. THESE COMPOUNDS ARE SELECTIVE AGONISTS OF DOPAMINE D3, AND ARE USEFUL IN THE TREATMENT AND / OR PREVENTION OF FEMALE OR MALE SEXUAL DYSFUNCTION AND RELATED DISEASES

PE2005000583A 2004-05-27 2005-05-25 AMINOPYRIDINE DERIVATIVES AS DOPAMINE AGONISTS PE20060366A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411891A GB0411891D0 (en) 2004-05-27 2004-05-27 New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en) 2004-06-03 2004-06-03 New aminopyridine derivatives and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
PE20060366A1 true PE20060366A1 (en) 2006-05-15

Family

ID=34970000

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000583A PE20060366A1 (en) 2004-05-27 2005-05-25 AMINOPYRIDINE DERIVATIVES AS DOPAMINE AGONISTS

Country Status (21)

Country Link
EP (1) EP1758862A1 (en)
JP (1) JP4198183B2 (en)
AP (1) AP2006003824A0 (en)
AR (1) AR049548A1 (en)
AU (1) AU2005247699A1 (en)
BR (1) BRPI0511571A (en)
CA (1) CA2567935C (en)
EA (1) EA200601982A1 (en)
EC (1) ECSP067029A (en)
GT (1) GT200500125A (en)
IL (1) IL179314A0 (en)
MA (1) MA28607B1 (en)
MX (1) MXPA06013786A (en)
NL (1) NL1029139C2 (en)
NO (1) NO20065326L (en)
PA (1) PA8635101A1 (en)
PE (1) PE20060366A1 (en)
SV (1) SV2005002129A (en)
TW (1) TW200609216A (en)
UY (1) UY28925A1 (en)
WO (1) WO2005115985A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502509D0 (en) * 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
US8957064B2 (en) * 2009-02-13 2015-02-17 Bayer Intellectual Property Gmbh Fused pyrimidines
MX355697B (en) * 2010-04-12 2018-04-27 Supernus Pharmaceuticals Inc Methods for producing viloxazine salts and novel polymorphs thereof.
BR112013034074B1 (en) 2011-06-30 2021-02-23 Donaldson Company, Inc filter cartridge and crankcase ventilation filter assembly
GB2543296A (en) 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
TWI712598B (en) 2016-07-20 2020-12-11 瑞士商諾華公司 Aminopyridine derivatives and their use as selective alk-2 inhibitors
US20220220102A1 (en) * 2019-04-12 2022-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
CN115038443A (en) 2019-11-22 2022-09-09 因西特公司 Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
IL298767A (en) 2020-06-16 2023-02-01 Incyte Corp Alk2 inhibitors for the treatment of anemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) * 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
WO2004052372A1 (en) * 2002-12-10 2004-06-24 Pfizer Limited Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction

Also Published As

Publication number Publication date
NL1029139A1 (en) 2005-11-30
NL1029139C2 (en) 2006-06-19
CA2567935A1 (en) 2005-12-08
EP1758862A1 (en) 2007-03-07
MXPA06013786A (en) 2007-01-25
AR049548A1 (en) 2006-08-16
TW200609216A (en) 2006-03-16
MA28607B1 (en) 2007-05-02
ECSP067029A (en) 2006-12-29
AP2006003824A0 (en) 2006-12-31
AU2005247699A1 (en) 2005-12-08
EA200601982A1 (en) 2007-04-27
NO20065326L (en) 2006-12-19
IL179314A0 (en) 2007-03-08
UY28925A1 (en) 2005-12-30
JP2008500331A (en) 2008-01-10
SV2005002129A (en) 2005-12-13
WO2005115985A1 (en) 2005-12-08
BRPI0511571A (en) 2008-01-02
JP4198183B2 (en) 2008-12-17
GT200500125A (en) 2006-01-10
PA8635101A1 (en) 2006-05-16
CA2567935C (en) 2009-10-27

Similar Documents

Publication Publication Date Title
PE20060366A1 (en) AMINOPYRIDINE DERIVATIVES AS DOPAMINE AGONISTS
PE20070833A1 (en) PYRIMIDINYL BENZOTHIOPHENE COMPOUNDS
PE20060937A1 (en) SULFONYLBENZIMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 2 (CB2) AGONISTS
PE20070136A1 (en) COMPOUNDS DERIVED FROM N- (PYRIDIN-2-IL) -SULFONAMIDE AS INHIBITORS OF THE ENZYME 11-beta-HYDROXIESTEROID DEHIDROGENASE HUMAN TYPE 1
MY133385A (en) Benzazoles: benzoxazoles, benzthiazole and benzimidazole derivatives
MY142807A (en) Benzimidazole derivative and use thereof.
PE20121157A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SERINE PROTEASES
PE20091843A1 (en) CATEPSIN C INHIBITORS
PE20060625A1 (en) BENZAZEPINE DERIVATIVES AS ANTAGONISTS AND / OR AGONISTS OF THE HISTAMINE H3 RECEPTOR
PE20061353A1 (en) SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORS
PE20081545A1 (en) SULFONAMIDE DERIVATIVES AS SYNTHASE FATTY ACID INHIBITORS
AR004002A1 (en) COMPOSITION USEFUL ESPECIALLY FOR THE TREATMENT AND PROTECTION OF DOMESTIC ANIMALS INFESTED OR LIKELY TO BE INFESTED BY PARASITES
PE20080768A1 (en) ISOINDOLINE 5-SUBSTITUTE COMPOUNDS
PE20100562A1 (en) POLYCYCLICAL DERIVATIVES OF INDAZOL AS INHIBITORS OF ERK
PE20080318A1 (en) DICETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
PE20081836A1 (en) PIPERIDINE DERIVATIVES AS INHIBITORS OF FATTY ACID SYNTHASE
PE20050072A1 (en) NEW IMIDAZOLE COMPOUNDS AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
PE20050864A1 (en) HETEROCICLYLAMINE COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1
PE20121506A1 (en) TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
PE20130385A1 (en) DERIVATIVES OF NAFT-2-ILACETIC ACID TO TREAT AIDS
PE20090290A1 (en) PYRROLOPYRIDINE DERIVATIVES AS BACE INHIBITORS
PE20120691A1 (en) DERIVATIVES OF N1-SULFONYL-5-FLUOROPYRIMIDINONE
PE20060691A1 (en) SERINAMIDES REPLACED BY BENZOYL
PE20090601A1 (en) PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS
PE20060455A1 (en) 3-BETA-D-RIBOFURANOSYLTIAZOLE [4,5-D] PYRIMIDINE NUCLEOSIDES

Legal Events

Date Code Title Description
FD Application declared void or lapsed